Table 4.

Incidence of neurologic effects (limb impairment) following epidural and intrathecal injection

	Number of animals with clinical signs of limb impairmenta
	Study day (postdosing)
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
Epidural treatment (day 1)b
Liposome bupivacaine 40 mg	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposome bupivacaine 40 mg with lidocaine/epinephrine	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bupivacaine HCl 15 mg	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Placebo	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Saline	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intrathecal treatment (day 1)b
Liposome bupivacaine 40 mg	4	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Bupivacaine HCl 15 mg	6	3	3	3	3	3	3	1	0	0	0	0	0	0	0	0	0
Placebo	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Saline	2	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0

Notes:

^aNo animals had clinical signs of limb impairment beyond day 17 until the last day of observation (ie, day 22);

^bsix male dogs per group.